Literature DB >> 3669023

1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity.

K Shyam1, R T Hrubiec, R Furubayashi, L A Cosby, A C Sartorelli.   

Abstract

A series of 1,2-bis(sulfonyl)hydrazines was synthesized and evaluated for antineoplastic activity against the L1210 leukemia and the B16 melanoma. The most active agent to emerge from this study, 1,2-bis(methylsulfonyl)-1-methylhydrazine, produced a maximum % T/C for mice bearing the L1210 leukemia or the B16 melanoma of 340% and 278%, respectively. Two N-chloroethyl analogues, conceived as bifunctional alkylating agents, were also synthesized and evaluated for antineoplastic activity against the L1210 leukemia and the B16 melanoma. Although such a modification resulted in retention of antineoplastic activity against both tumor cell lines, it did not result in enhanced antineoplastic activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3669023     DOI: 10.1021/jm00394a040

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  In vitro evaluation of 3-arylcoumarin derivatives in A549 cell line.

Authors:  Musiliyu A Musa; Moise Y Joseph; Lekan M Latinwo; Veera Badisa; John S Cooperwood
Journal:  Anticancer Res       Date:  2015-02       Impact factor: 2.480

2.  Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.

Authors:  Kimiko Ishiguro; Yong-Lian Zhu; Krishnamurthy Shyam; Philip G Penketh; Raymond P Baumann; Alan C Sartorelli
Journal:  Biochem Pharmacol       Date:  2010-07-21       Impact factor: 5.858

3.  Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rat.

Authors:  John Mao; Yang Xu; Diana Wu; Bijan Almassain
Journal:  AAPS PharmSci       Date:  2002

4.  Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.

Authors:  G Krishna; W F Hodnick; W Lang; X Lin; S Karra; J Mao; B Almassian
Journal:  AAPS PharmSciTech       Date:  2001-08-26       Impact factor: 3.246

5.  A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer.

Authors:  John Murren; Manuel Modiano; Shivaani Kummar; Caroline Clairmont; Merrill Egorin; Edward Chu; Mario Sznol
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.651

6.  Influence of glutathione and glutathione S-transferases on DNA interstrand cross-link formation by 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine, the active anticancer moiety generated by laromustine.

Authors:  Philip G Penketh; Eric Patridge; Krishnamurthy Shyam; Raymond P Baumann; Rui Zhu; Kimiko Ishiguro; Alan C Sartorelli
Journal:  Chem Res Toxicol       Date:  2014-07-17       Impact factor: 3.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.